News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Xanthus Pharmaceuticals, Inc. Initiates a Phase 1 Study of Clomet for Treatment of Solid Tumors
March 22, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals today announced the commencement of a Phase 1 dose escalation study of Clomet™ (DMPEN, 4-demethylpenclomedine) for the treatment of patients with solid tumors.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
IN PARTNERSHIP WITH GEMPHARMATECH
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
September 2, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Multiple sclerosis
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
September 2, 2026
·
2 min read
·
Tristan Manalac
FDA
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
September 2, 2026
·
2 min read
·
Jef Akst
Cancer
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
September 1, 2026
·
2 min read
·
Annalee Armstrong
